Cover Page

Universiteit Leiden

The handle http://hdl.handle.net/1887/38587 holds various files of this Leiden University dissertation.

Author: Suurmond, Jolien
Title: Immune regulation by mast cells
Issue Date: 2016-03-22

MAST CELLS IN RHEUMATIC DISEASE

Chapter 11

Jolien Suurmond,[1,†] Daniël van der Velden, [1,2,†]
Johan Kuiper,[2] Ilze Bot, [2] René EM Toes[1]

[1]Department of Rheumatology, Leiden University Medical Center, Leiden,
The Netherlands; [2]Division of Biopharmaceutics, Leiden Academic Centre for
Drug Research, Leiden, The Netherlands

[†]These authors contributed equally to this work.

ABSTRACT

Rheumatoid Arthritis is a chronic autoimmune disease with a complex disease pathogenesis leading to inflammation and destruction of synovial tissue in the joint. Several molecules lead to activation of immune pathways, including autoantibodies, Toll-Like Receptor ligands and cytokines. These pathways can cooperate to create the pro-inflammatory environment that results in tissue destruction. Each of these pathways can activate mast cells, inducing the release of a variety of inflammatory mediators, and in combination can markedly enhance mast cell responses.

Mast cell-derived cytokines, chemokines, and proteases have the potential to induce recruitment of other leukocytes able to evoke tissue remodeling or destruction. Likewise, mast cells can secrete a plethora of factors that can contribute to tissue remodeling and fibroblast activation. Although the functional role of mast cells in arthritis pathogenesis in mice is not yet elucidated, the increased numbers of mast cells and mast cell-specific mediators in synovial tissue of rheumatoid arthritis patients suggest that mast cell activation in rheumatoid arthritis may contribute to its pathogenesis.

PATHOGENIC PATHWAYS IN RHEUMATOID ARTHRITIS

Rheumatoid arthritis is a systemic autoimmune disease characterized by chronic inflammation of the synovial lining of the joint, and is one of the most common autoimmune diseases affecting approximately 1% of the general population (*1*). Synovitis, inflammation of the synovial tissue, is mediated through leukocyte infiltration of the tissue, and leads to hyperplasia of fibroblast-like synoviocytes and tissue remodeling. Likewise, synovitis can induce cartilage destruction and bone erosion, ultimately leading to destruction of the joint. Clinically, synovitis induces pain and swelling of the involved joints, and the tissue destruction evoked can lead to disabilities if left untreated.

It is currently believed that different cells of the immune system play a role in the pathogenesis of rheumatoid arthritis. However, the exact cause of rheumatoid arthritis is not known. Genetic risk factors (such as HLA) underlying disease susceptibility are often involved in T- and B-cell responses and the presence of activated B cells and T cells in the inflamed synovium of rheumatoid arthritis patients indicate that adaptive immunity plays a prominent role. Furthermore, the presence of autoantibodies in the majority of patients points towards an important role for B cells in rheumatoid arthritis. However, besides the role of adaptive immune cells in initiation of autoreactive responses, innate immune cells are thought to play an important role during the effector phase by sustaining inflammation.

Treatment is usually aimed at lowering disease activity via immunosuppression, which can be achieved in various ways including through the interference with B cell-mediated immunity, co-stimulatory pathways, and inhibition of proinflammatory cytokines, suggesting that these pathways play an important role in disease pathogenesis.

AUTOANTIBODIES

A major effector function thought to contribute to pathogenesis in rheumatoid arthritis is mediated by autoantibodies. The classical autoantibody system associated with rheumatoid arthritis is rheumatoid factor, which recognizes the Fc portion of IgG. However, rheumatoid factor is not specific for rheumatoid arthritis patients, as it is also produced in a number of other inflammatory conditions, therefore its role in disease pathogenesis is often questioned.

An important group of autoantibodies in rheumatoid arthritis targets modified proteins, with anti-citrullinated protein antibodies (ACPA) being the most well-characterized. These antibodies recognize a variety of proteins or peptides in which the amino acid arginine is modified into a citrulline through a posttranslational modification process mediated by Peptidyl Arginine Deiminase (PAD) enzymes. PAD enzymes are normally present inside cells and can be activated by high calcium levels when cells, such as neutrophils, undergo apoptosis, an event readily occurring during inflammation (*2*). PAD enzymes that are transported to the outside of cells can citrullinate the extracellular matrix and in doing so can create targets for ACPA. Citrullinated proteins can be found in a variety of inflamed tissues, including the synovial tissue of rheumatoid arthritis patients (*3, 4*). ACPA can recognize many citrullinated proteins such as vimentin, filaggrin, and fibrinogen. Because fibrinogen and vimentin are also present in the extracellular matrix of the synovium, these proteins are often considered as important target antigens for ACPA (*5*).

ACPA show a very high specificity for rheumatoid arthritis, and are present in the majority (~70%) of rheumatoid arthritis patients (*6, 7*). Since their discovery ACPA are mainly used as diagnostic marker. However, it is now becoming increasingly clear that ACPA might also play a functional role in the pathology of rheumatoid arthritis. Several observations underlie this notion. ACPA can be observed already years before the onset of symptoms, and rarely develop after onset of clinical manifestation of rheumatoid arthritis (*8, 9*). The latter indicates that it is not likely that ACPA are a consequence of the inflammation present in rheumatoid arthritis patients. ACPA+ and ACPA- patients differ considerably with respect to the underlying genetic and environmental risk factors, suggesting that rheumatoid arthritis consists of two different disease entities: ACPA+ and ACPA- rheumatoid arthritis (*10-13*). Furthermore,

11

ACPA+ and ACPA- rheumatoid arthritis patients have a different disease course with ACPA+ patients having a more progressive disease, characterized by increased radiological joint damage and worse disease activity scores (*9, 14*). These findings suggest that ACPA contribute to disease pathogenesis. When ACPA antibodies are adoptively transferred into mice with a low-level synovial inflammation caused by anti-collagen antibodies, ACPA (reactive with citrullinated fibrinogen or collagen II) could enhance arthritis, implicating their direct involvement in the inflammatory process (*15, 16*).

Other autoantibodies present in rheumatoid arthritis patients include antibodies directed against carbamylated proteins, or anti-Carbamylated Protein Antibodies (anti-CarP), another autoantibody directed towards modified proteins. Like ACPA, Anti-CarP are present before disease onset and associate with disease severity in (ACPA-negative) rheumatoid arthritis patients, and could potentially contribute to disease pathogenesis (*17*).

TOLL LIKE RECEPTOR LIGANDS

Toll like receptor (TLR) activation is another important pathway for immune activation in rheumatoid arthritis. Although TLR are particularly known for their role in protection against pathogens, through their recognition of pathogen associated molecular patterns, endogenous ligands have been reported to trigger these receptors as well. Such endogenous ligands are present in conditions of stress or tissue damage, and often are intracellular molecules that can be either passively or actively released upon cell death. As rheumatoid arthritis, like other inflammatory conditions, is related to tissue destruction, cell death and the associated presence of endogenous TLR ligands is a common feature in synovium of patients. Several examples have been described of damage associated endogenous TLR ligands present in synovium, including HMGB1, heat shock proteins, tenascin c, and fibronectin (*18-22*). These endogenous ligands are thought to contribute to the chronicity of inflammation, as they can activate TLRs, inducing an inflammatory response, further tissue and cellular damage, and thereby the sustained release of damage associated TLR ligands.

Next to damage-associated TLR ligands, cell death can also lead to release of PAD enzymes into the extracellular environment, leading to generation of citrullinated proteins, including fibrinogen. Citrullinated fibrinogen, one of the antigens recognized by ACPA, was shown to trigger TLR-4 (*23*). Therefore, chronic inflammation is often related to release or generation of TLR ligands, leading to a self-amplifying inflammatory loop (Fig. 1).

T HELPER CELLS

The strong genetic association of the HLA region with disease susceptibility suggests the involvement of T helper cells in the etiology of rheumatoid arthritis. The association to HLA-DR alleles is not completely understood, but is specifically related to the ACPA response and could therefore be attributed to the helper function of T cells by which they can drive autoantibody responses by B cells (13). However, T cells themselves may also exert pathogenic effects, for example through their production of cytokines. Initially, Th1 cells, producing IFNγ and TNFα were thought to drive the immune response in rheumatoid arthritis. Since discovery of a wide variety of T helper cell subsets, Th17 cells (producing IL-17) have been proposed as the most relevant subset of T cells in relation to arthritis, although their putative role in- or contribution to the pathogenesis of rheumatoid arthritis in humans is unclear (24).

CYTOKINES AND CHEMOKINES: INFLAMMATORY MEDIATORS

The importance of proinflammatory cytokines in the pathogenesis of rheumatoid arthritis is well established. The development of biologic agents that target various immune mediators has dramatically improved the patient prognosis in the past decades, and most of these biologicals target cytokines or cytokine receptors. Established and approved therapies for rheumatoid arthritis block cytokine responses to TNF and IL-6 (25). Cytokines are produced in response to immune cell activation, and can activate cells in an autocrine, paracrine or systemic manner, leading to gene transcription of other cytokines, MMPs and other proinflammatory molecules. Thereby they contribute to the self-amplifying loop of immune activation. The cytokines mentioned above have a variety of target cells and functions, thereby able to trigger tissue inflammation, cartilage destruction, bone erosion and angiogenesis.

11

ACTIVATION OF MAST CELLS IN RHEUMATOID ARTHRITIS

The mast cell is a potent immune cell from the myeloid lineage and is well-known for its granules containing inflammatory mediators which can be rapidly released upon activation. Mast cells reside at interfaces with the external environment, where they act as first line of defense against invading pathogens, such as parasites and bacteria. In addition, mast cells play an important role in allergic diseases (26). As there is overlap in the mechanisms involved in hypersensitivity in allergy and autoimmune diseases, a role for mast cells in autoimmune disease has long been postulated. Several clinical findings support an active role of mast cells in rheumatoid arthritis pathogenesis, and suggest that mast cells are activated in the synovium of rheumatoid arthritis patients.

MAST CELL HYPERPLASIA IN SYNOVIUM

It has been shown that increased numbers of mast cells are present in synovium of rheumatoid arthritis patients, with numbers up to 5% of the total cell number in synovium (*27, 28*). Increased mast cell numbers, or so-called mast cell hyperplasia, is a hallmark of multiple autoimmune diseases. Growth factors and cytokines in synovial tissue, such as stem cell factor, the critical growth factor for mast cell survival, as well as IL-3 and IL-4 are present in synovial tissue of rheumatoid arthritis patients. These mediators can induce proliferation of mast cells, whereas in addition, stem cell factor and TGFβ have been shown to induce recruitment of mast cells (*29*), suggesting that the accumulation of mast cells in synovium may be the consequence of an ongoing inflammatory response mediating mast cell expansion through increased recruitment and proliferation.

In addition to the accumulation of mast cells, it has been reported that the proportion of different mast cell subsets is changed in the synovium of rheumatoid arthritis patients. Two main subsets of mast cells exist based on the expression of proteases, divided in tryptase-only positive cells (MCT) and tryptase–chymase double-positive cells (MCTC). Whereas normal synovium mainly contains MCTC cells, early inflammation in rheumatoid arthritis is associated with a selective expansion of MCT, followed by increases of MCTC in established or chronic disease (*29-31*). These changes are often correlated with clinical characteristics; MCT numbers in early disease associate with inflammation, whereas the MCTC numbers in chronic disease associate with tissue remodeling features, which may underlie active involvement of both subsets in different pathological processes.

MAST CELL MEDIATORS IN SYNOVIAL TISSUE OR FLUID

Mast cells produce a range of mediators, through three major pathways of secretion. First of all, they are characterized by presence of intracellular granules, containing preformed mediators such as histamine, proteases, proteoglycans, and heparin, which are rapidly released upon degranulation. Certain activation pathways can induce the release of lipid-derived mediators, produced from arachidonic acid, such as leukotrienes and prostaglandins. Finally, mast cell activation induces gene transcription, leading to de novo synthesis of cytokines, chemokines and growth factors, which can be released within several hours of activation.

Although most of de novo-produced cytokines are not mast cell-specific, several preformed granule proteins are more or less specifically expressed by mast cells, including the mast cell specific proteases tryptase and chymase. Both histamine and

tryptase are elevated in synovial fluid of rheumatoid arthritis patients likely reflecting local mast cell activation (*28, 32-34*). Furthermore, mast cells have been reported to be the main IL-17-positive cells in the inflammatory joint of rheumatoid arthritis and spondyloarthropathy patients (*35*). As discussed below, several of these mediators can contribute significantly to inflammation in the joint.

MAST CELL ACTIVATION PATHWAYS IN RHEUMATOID ARTHRITIS

Mast cells are most well-known because of their role in IgE-mediated immune responses as they express the high affinity FcεRI, and therefore have originally mainly been considered for their role in allergic diseases. However, the importance of mast cells in IgE-independent responses has been appreciated in the last decades, and has led to increased understanding of mast cell function in a variety of immune responses, including autoimmune disease.

Mast cell activation by autoantibodies

Depending on their specific isotype, antibodies can exert immune activation by binding to cellular Fc receptors and activation of complement. Because various isotypes of ACPA (IgG, IgA, IgM) have been previously demonstrated, ACPA are, in principle, able to activate the immune system via both pathways (*36*). The potential of ACPA to activate complement has been shown in vitro. ACPA bound to immobilized antigen activated the complement system, via both the classical and alternative pathways (*37*). These pathways can activate mast cells, for examples through the cleavage product C5a. It has been shown in mice that C5aR activation of synovial mast cells is essential for the induction of arthritis (*38*). However, in humans, it is not clear whether this pathway contributes to autoantibody-mediated mast cell activation.

Besides indirect activation of immune cells via complement activation, autoantibodies can also directly activate cells upon crosslinking of Fc receptors, in particular Fcγ receptors (binding IgG), Fcε receptors (IgE), and Fcα receptors (IgA). As ACPA are mainly present as IgM and IgG isotypes, the binding of IgG-ACPA to Fcγ receptors is thought to play a major role in autoantibody-mediated pathogenesis. Activating Fc receptors are predominantly expressed by myeloid immune cells, including mast cells. In mice, certain mast cell subsets, including synovial mast cells, express the activating FcγRIIIa (*39-41*), the receptor involved in arthritis induced by anti-collagen autoantibodies (*42*). Human mast cells have been shown to express FcγRIIA, whereas there is some controversy regarding expression of FcγRI (*43-45*). We have recently shown that human cultured mast cells could be activated by ACPA immune complexes in a citrulline-dependent manner (*45*). This activation was mediated through crosslinking FcγRIIA. As this receptor was expressed by synovial mast cells from all

11

patients analysed, we propose that this receptor is a major player in autoantibody-mediated mast cell activation.

Mast cell activation by Toll like receptor ligands

Toll like receptors (TLRs) are expressed by a variety of immune cells, and are considered to act as sentinels of the immune system. As mast cells are thought to play an important role in protection against pathogens, their expression of TLRs has been studied in different cell subsets and species. Although some variation is present in expression of these receptors, mast cells generally express a wide variety of TLRs, and triggering of TLR by pathogen associated molecular patterns induces activation of mast cells (*46-49*). Importantly, mast cells also express those TLRs that are thought to mediate responses to endogenous ligands released in inflammatory conditions. The main receptors involved in such responses are TLR-2, TLR-4 and endosomal TLRs which sense nucleic acids (*20, 50*).

We have recently shown that human mast cells indeed respond to HSP70, an endogenous ligand for TLR-4, which is present in rheumatoid arthritis synovium (*45*). Another endogenous TLR ligand, the extra domain A of fibronectin, can induce joint inflammation in mice in a mast cell- and TLR4-dependent manner (*18*), suggesting that this pathway of mast cell activation can contribute to pathogenic responses in rheumatoid arthritis.

Mast cell activation by cytokines

As described above, several cytokines or growth factors are involved in survival and expansion of mast cells in synovium. In addition, cytokines can activate mast cells directly. Such cytokines include IL-3, IL-4, IL-5, and IL-33, each of which are increased in synovial tissue or fluid of rheumatoid arthritis patients. However, stimulation of mast cells with cytokines alone usually mediates mainly proliferation with only a low level of activation. Importantly, the cytokine environment can play an important role in priming of mast cell responses to other triggers (*51*). IL-33 has been shown to enhance arthritis in a mast cell-dependent manner (*52*), suggesting that activation or priming of mast cells by cytokines can significantly alter inflammatory responses in the joint.

Mast cell-T cell interactions

The interaction between mast cells and T helper cells has been explored in recent years. In both human and mouse, mast cells have been shown to present antigens to CD4[+] T cells, thereby enhancing T cell responses with the possibility of skewing specific T helper subsets as well (*53-55*). Besides antigen presentation, mast cell-derived cytokines can also induce T cell activation (*56*).

Although we have recently shown that the interaction between T helper cells and mast cells does not only activate T cells, but can also change mast cell phenotype, the exact influence of T cells on mast cell function has been studied sparsely (*57*). Whereas regulatory T cells can inhibit mast cell activation, the effect of T cells involved in rheumatoid arthritis, such as Th17 cells, is not known (*58, 59*). However, these cell types are likely to interact and it is tempting to speculate that such an interaction contributes to pathogenesis of rheumatoid arthritis. A recent study indeed suggested that mast cells can regulate T cell responses in an arthritis mouse model, by inducing CD4[+] T cell expansion and Th1 and Th17 cytokine secretion (*60*).

CHRONIC INFLAMMATION MEDIATED BY A COMPLEX INTERPLAY OF MULTIPLE PATHWAYS

As rheumatoid arthritis is characterized by the activation of multiple immune pathways, these pathways are likely to interact. For example, it has been shown for different types of myeloid cells that activation through TLRs synergizes with triggering of Fc receptors (*45, 61, 62*). As mast cells can be activated by different cytokines, several studies have investigated the interaction between cytokine- and FcεRI-mediated activation. These studies have shown increased degranulation and cytokine production when mast cells are exposed to combined triggers of e.g. IL-3, IL-4 and IL-33 with FcεRI crosslinking (*63-66*). Whereas these studies are important for understanding of the role of cytokines in allergic responses, Fcγ receptors, as compared to FcεRI, are probably more important for mast cell activation in rheumatoid arthritis.

In this context, IL-33 was shown to enhance immune complex mediated mast cell responses through Fc γ receptors (*67*). In addition, we have studied the interaction of Toll Like receptor triggering on Fcγ receptor mediated mast cell activation, and shown that this greatly enhanced cytokine production by human mast cells (*45*). Importantly, we also showed this interaction was present in an antigen-specific system using ACPA autoantibodies and endogenous TLR ligands present in synovium.

Such a synergy between TLR or cytokines and Fc receptor responsiveness likely represents a physiological function of the immune system to mount an enhanced response when antibodies are produced after the first encounter of a pathogen (*68*). Whereas this is conceivably highly beneficial when a pathogen needs to be eliminated, such responses in an autoimmune setting can drive chronic inflammation, because it can lead to further release of modified self-antigens and TLR ligands (Fig. 1). Therefore, synergy in mast cell responses may contribute to chronicity of rheumatoid arthritis.

11

Figure 1. Chronic inflammation in rheumatoid arthritis is amplified by mast cells. Damage associated Toll Like Receptor (TLR) ligands, cytokines and citrullinated proteins are all implicated in rheumatoid arthritis pathogenesis and are released upon inflammation, in particular in association with cell death. Both have been shown to activate mast cells: citrullinated proteins can form immune complexes with ACPA autoantibodies, and activate mast cells through Fcγ receptors; endogenous ligands can activate mast cells through TLRs; various cytokines can activate mast cells. In the environment of the inflamed joint, all of these triggers are present at the same time, and together lead to synergy in mast cell activation. This synergy leads to enhanced tissue inflammation, in particular neutrophil influx, leading to cell death in the tissue. This cell death can lead to an amplification loop by generating more endogenous TLR ligands and citrullinated proteins.

MAST CELL EFFECTOR FUNCTIONS IN RHEUMATOID ARTHRITIS

Mast cells are well-known for their potent and quick effector functions, such as present during allergic reactions. However, as tissue-resident cells, their physiological role is thought to be protection against pathogens, as well as to contribute to wound healing (*69*). Therefore, it is not surprising that they also contribute to these processes during autoimmune responses.

MAST CELL-MEDIATED TISSUE INFLAMMATION

During certain bacterial infections, mast cells can orchestrate a local inflammatory response by rapidly increasing vascular permeability and releasing chemokines. Thereby they contribute to the recruitment of neutrophils and other immune cells, ultimately resulting in amplification of the local inflammatory response (*70*). Rheumatoid arthritis is

also characterized by accumulation of immune cells. Whereas the synovial lining mainly contains monocytes/macrophages and T cells, synovial fluid is the site to which neutrophils are recruited. In humans, it has been shown that neutrophil chemoattraction to the synovial fluid is mainly mediated by IL-8, a cytokine produced (although not exclusively) by mast cells in response to ACPA autoantibodies and TLR ligands (*45, 71, 72*). In mice, mast cell-derived TNF and leukotriene B4 can both mediate neutrophil recruitment as well (*73-76*). In addition, histamine can increase vascular permeability, thereby augmenting neutrophil recruitment (Fig. 2A) (*77*). These and other mast cell-derived chemokines can also induce recruitment of T cells and monocytes, although evidence indicating that this also occurs in the context of autoimmunity is scarce. Growth factors for neutrophils and macrophages, such as GM-CSF and G-CSF are also produced by mast cells, suggesting that besides inducing cellular infiltration, mast cells may also contribute to survival of these cell subsets.

CROSSTALK BETWEEN SYNOVIAL FIBROBLASTS AND MAST CELLS

An important consequence of the chronic tissue inflammation present in rheumatoid arthritis is activation of synovial fibroblasts, also called fibroblast-like synoviocytes, the main stromal cell type of the synovium. Activation of synoviocytes in rheumatoid arthritis leads to their proliferation and reduced apoptosis, secretion of cytokines and chemokines and invasiveness, whereby synoviocytes invade the underlying cartilage/collagen tissue (*78*) Synovial fibroblasts can be activated by multiple pathways, including TLR activation, and cytokines (*79*). Cytokines implicated in this process are TNFα, IL-1, and IL-17 (*80, 81*). Mast cells can produce each of these cytokines, thereby potentially contributing to activation of synovial fibroblasts (Fig. 2B). In addition, other mast cell mediators, such as histamine and tryptase have been shown to induce activation and inhibition of apoptosis in synovial fibroblasts cells as well (*82, 83*) Likewise, interaction between synovial fibroblasts can also lead to bi-directional crosstalk, whereby fibroblasts recruit and activate mast cells, for example through stem cell factor and IL-33 (*52*)

TISSUE REMODELING SUSTAINED BY MAST CELLS

Tissue inflammation and activation of fibroblasts goes hand-in-hand with various tissue remodeling processes, characterized by angiogenesis, breakdown of cartilage and bone erosion. Angiogenesis occurs mainly in the synovial lining of the joint, where rapid-growing fibroblasts and infiltrating immune cells require increased amounts of nutrients and oxygen supplied through the blood. Angiogenesis is mediated by growth factors such as VEGF and FGF, and angiogenic cytokines such as IL-8, TNF and GM-CSF, but can also be mediated by mast cell granule-derived mediators such as heparin, tryptase and chymase

(Fig. 2C) (*84-87*). Mast cells are often found in close proximity to blood vessels, and their numbers are often associated with angiogenesis, especially in the context of tumors and wound healing (*88, 89*). Although no functional data are available on the direct role of mast cells in synovial angiogenesis, their secretion profile suggests that they may contribute this process.

Figure 2. Mast cell contribution to pathogenic processes in rheumatoid arthritis. (A) Activated mast cells can amplify tissue inflammation through several mechanisms. They increase vascular permeability through release of histamine, leading to increased recruitment of immune cells. In particular, neutrophils are recruited into synovial fluid by chemokines such as IL-8, TNFα, and leukotrienes, whereas monocytes and T cells are recruited to the synovial tissue through chemokines such as TNF, CCL2, and CCL5. (B) Mast cells in synovium have a bidirectional interaction with fibroblasts, whereby fibroblasts can activate mast cells through growth factors and cytokines (SCF, IL-33), and activated mast cells in turn can activate synovial fibroblasts. Mast cell degranulation can induce proliferation of fibroblasts by histamine and tryptase, and cytokine production by mast cells (TNFα, IL-1, IL-17) can led to activation of synovial fibroblasts. Together, this crosstalk can induce fibroblasts invading into the underlying cartilage tissue. (C) Mast cell-derived cytokines and proteases can contribute to increased angiogenesis, a process required for the increased metabolic demand in inflamed tissue. Furthermore, various mast cell proteases can lead to extracellular MMP cleavage, leading to their activation, a crucial process in the breakdown of cartilage.

The two main destructive processes in rheumatoid arthritis are cartilage breakdown and bone erosion. Synovial fibroblasts, next to chondrocytes have been implicated in cartilage breakdown. Both cell types secrete matrix degrading enzymes such as matrix metalloproteinases (MMPs) (*90*). These enzymes can break down extracellular matrix proteins such as collagen, aggrecan and fibrinogen.

An important feature of MMPs is their secretion as inactive pro-enzymes which need to be cleaved by other MMPs or other proteinases to become activated (*91*). As this cleavage occurs in the extracellular space, the proteases required for cleavage can be derived from different cellular origins. In this respect, mast cell tryptase could play a prominent role as it is known for its ability to activate MMPs (*92, 93*). In doing so, mast cells can contribute to loss of cartilage through activation of MMPs via secretion of tryptase (Fig. 2C).

Osteoclast activation is the main mechanism leading to bone erosions. Although mast cells are not known to release RANKL, a major factor involved in osteoclast activation, mast cells may contribute to setting the balance in bone homeostasis. For example, patients with mastocytosis (systemic mast cell hyperplasia) exhibit features of accelerated bone turnover, possibly through a direct effect of histamine on osteoclasts (*94, 95*).

In summary, mast cells can secrete a variety of mediators which are implicated in many of the basic pathogenic hallmarks of rheumatoid arthritis.

MOUSE MODELS FOR ARTHRITIS AND MAST CELL INVOLVEMENT

ARTHRITIS MOUSE MODELS

Insight in the contribution of mast cells to pathogenesis of rheumatoid arthritis has also been obtained using models of experimental arthritis.

The first study to show an important role for mast cells in arthritis was performed in mice deficient in kit signaling, KitWKitW-v mice. In this study, experimental arthritis, induced by K/BxN serum transfer, was completely abolished in the absence of mast cells. Transfer of cultured bone marrow derived wild-type mast cells to mast cell deficient mice restored the incidence of arthritis after K/BxN serum transfer, indicating a direct effector function of mast cells in the development of arthritis (*96*). The critical role of mast cells for development of arthritis in this model has boosted the recognition of mast cells as a non-redundant cell in the development of autoimmune disease.

However, the findings from this study have been recently challenged in different models (Table 1). First of all, KitW-Sh/KitW-Sh mice, another mast cell deficient mouse due to defect kit signaling, were able to develop arthritis after passive transfer of anti-collagen type II antibodies (*97*). In addition, KitWKitW-v mice had normal arthritis development in the collagen induced arthritis model (*98*). Unlike neutropenic KitWKitW-v mice, KitW–sh/W–sh mice have a baseline pro-inflammatory phenotype, including neutrophilia (*99, 100*). Therefore, these confounding results have sometimes been attributed to the neutrophilia in KitW–sh/W–sh mice, which renders them insensitive to mast cell-mediated neutrophil recruitment, a critical event in early arthritis development (*101*).

Of the mast cell deficient mouse models independent of kit, two models have been used to study arthritis. In one study, the Cpa3Cre/+ mice, which are mast cell deficient, were fully susceptible to the induction of serum-induced arthritis and clinical scores, histology and gene expression analysis were comparable to wild-type mice (*102*). Therefore, it was concluded that the role of mast cells in arthritis is limited. Whereas mast cell deficiency using Mcpt5-Cre iDTR mice did not affect serum-induced arthritis either, these mice experienced reduced arthritis upon immunization with collagen (*60*), suggesting that further research is needed to increase our understanding of these discrepancies.

Despite these contradictory findings using mice with a complete mast cell deficiency, additional evidence for mast cell-mediated pathogenesis in arthritis comes from studies using mice deficient in mast cell-specific proteases, such as chymase or tryptase. Mice deficient in mMCP4, the homologue of human chymase, develop less severe arthritis upon collagen induced arthritis (*103*). Mice which are deficient in either tryptase mMCP6 and/or -7, especially in combination with heparin-deficiency, display a reduced severity of adjuvant-induced arthritis and K/BxN induced arthritis (for mMCP6 deficiency) (*104, 105*). In addition, mast cell-specific (Mcpt5-Cre-mediated) deficiency in A20, a regulatory molecule, leads to increased mast cell activation, thereby exacerbating collagen induced arthritis (*106*).

As most of these mouse models contain a single deficiency in a mast cell-specific mediator, and are therefore not associated with any other defects such as the kit mutant mice, these studies provide compelling evidence for mast cell involvement in arthritis, despite the contrasting data obtained with mast cell deficient mouse models. Therefore, more research is needed to increase our understanding of the role of mast cells in rheumatoid arthritis.

Table 1. Overview of experimental arthritis in MC-deficient or MC protease-deficient mice.

Mouse strain	Deficiency	Arthritis model	Outcome	Refs
Mast cell deficiency				
Kit^{W}Kit^{W-v} (W/W^v)	SCF-receptor mutation	K/BxN	Mast cell deficient mice resistant to develop arthritis.	96, 109
		CIA	No effect of mast cell deficiency	98
Kit^{W-Sh}/Kit^{W-Sh}	SCF-receptor mutation	α-collagen type II antibody transfer	No effect of mast cell deficiency	97
Cpa3-Cre (cre-master)	Cre-mediated tocxicity	K/BxN	No effect of mast cell deficiency	102
Mast cell protease-deficiency				
mMCP4-/-	Chymase	CIA	Reduced arthritis	103
mMCP6-/-, mMCP7-/-, NDST-2-/-	Tryptase/ heparin complexes	K/BxN	Reduced arthritis	105
		mBSA/IL-1β	Reduced arthritis	104
Mast cell-conditional knockout				
Mcpt5Cre A20Fl/Fl	A20	CIA	Exacerbated arthritis	106
Pharmacological mast cell inhibition				
Cromolyn	(not mast cell specific)	CIA	Reduced arthritis	109

mBSA: methylated bovine serum albumin; CIA: collagen-induced arthritis; K/BxN: SCF: stem cell factor.

PHARMACOLOGICAL INHIBITION OF MAST CELLS

As several lines of evidence suggest a role for mast cells in rheumatoid arthritis, intervention with mast cell activation could potentially form novel therapies. The drug cromolyn is clinically used as a treatment for asthma patients. The exact mechanism of cromolyn in not completely understood, but it is described to prevent the release of mast cell specific mediators like histamine from rat peritoneal cells (*107*). Cromolyn is described as a mast cell stabilizing agent and is used frequently in mouse studies. The effect of cromolyn as a prolactive on CIA was investigated in DBA/1 mice. A lower clinical score and radiographic score were observed compared to non-treated mice, when cromolyn was administered when first symptoms of clinical arthritis became evident (*108*). In addition, it was shown that intra-articular treatment of cromolyn or salbutamol prevented angiogenesis, pannus formation and joint destruction in mice (*109*).

Recently however, the specificity of cromolyn and the sensitivity of different types of mast cells to cromolyn in mice is under debate (*110*). Also, the specificity of salbutamol can be questioned since it has also inhibits the secretion of pro-inflammatory cytokines by macrophages and T cells (*109*). Therefore, development of mast cell-specific therapeutics is needed to establish the exact role of mast cells in rheumatoid arthritis.

CONCLUSIONS

Rheumatoid arthritis is a complex autoimmune disease caused by environmental and genetic interactions leading to a chronic activation of many (immune) cells in the synovial tissue. The pathology of rheumatoid arthritis involves multiple activation pathways and interactions between a variety of cell types with arthritogenic functions leading to the progression of joint destruction.

Mast cells can also be found in rheumatoid arthritis tissue, which indicates a possible role for this potent cell in the disease pathology. Many in vivo arthritis studies in mice have aimed to clarify the precise role of mast cells. However, since mouse models do not fully reflect the disease process and as some models for mast cell deficiency have additional non-mast cell defects, it is difficult to assess the specific role of mast cells on disease pathogenesis in vivo.

Nevertheless, mast cells have the capacity to respond to a wide range of activating ligands in synovium and their effector functions likely reflect their potential role in pathogenesis of rheumatoid arthritis.

REFERENCES

1.   Gabriel SE, The epidemiology of rheumatoid arthritis. *Rheum Dis Clin North Am* 27, 269-81 (2001).

2.   Gyorgy B, Toth E, Tarcsa E, Falus A, Buzas EI, Citrullination: a posttranslational modification in health and disease. *Int J Biochem Cell Biol* 38, 1662-77 (2006).

3.   Baeten D, Peene I, Union A *et al.*, Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. *Arthritis Rheum* 44, 2255-62 (2001).

4.   Makrygiannakis D, af Klint E, Lundberg IE *et al.*, Citrullination is an inflammation-dependent process. *Ann Rheum Dis* 65, 1219-22 (2006).

5. Klareskog L, Ronnelid J, Lundberg K, Padyukov L, Alfredsson L, Immunity to citrullinated proteins in rheumatoid arthritis. *Annu Rev Immunol* 26, 651-75 (2008).

6. Nishimura K, Sugiyama D, Kogata Y *et al.*, Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. *Ann Intern Med* 146, 797-808 (2007).

7. Schellekens GA, Visser H, de Jong BA *et al.*, The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. *Arthritis Rheum* 43, 155-63 (2000).

8. Rantapaa-Dahlqvist S, de Jong BA, Berglin E *et al.*, Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. *Arthritis Rheum* 48, 2741-9 (2003).

9. Ronnelid J, Wick MC, Lampa J *et al.*, Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. *Ann Rheum Dis* 64, 1744-9 (2005).

10. Huizinga TW, Amos CI, van der Helm-van Mil AH *et al.*, Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. *Arthritis Rheum* 52, 3433-8 (2005).

11. Klareskog L, Stolt P, Lundberg K *et al.*, A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. *Arthritis Rheum* 54, 38-46 (2006).

12. Pedersen M, Jacobsen S, Garred P *et al.*, Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. *Arthritis Rheum* 56, 1446-53 (2007).

13. van der Helm-van Mil AH, Verpoort KN, Breedveld FC *et al.*, The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. *Arthritis Rheum* 54, 1117-21 (2006).

14. Meyer O, Labarre C, Dougados M *et al.*, Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. *Ann Rheum Dis* 62, 120-6 (2003).

15. Kuhn KA, Kulik L, Tomooka B *et al.*, Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. *J Clin Invest* 116, 961-73 (2006).

16. Uysal H, Bockermann R, Nandakumar KS *et al.*, Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. *J Exp Med* 206, 449-62 (2009).

17. Shi J, Knevel R, Suwannalai P *et al.*, Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. *Proc Natl Acad Sci U S A* 108, 17372-7 (2011).

18. Gondokaryono SP, Ushio H, Niyonsaba F *et al.*, The extra domain A of fibronectin stimulates murine mast cells via toll-like receptor 4. *J Leukoc Biol* 82, 657-65 (2007).

19. Martin CA, Carsons SE, Kowalewski R *et al.*, Aberrant extracellular and dendritic cell (DC) surface expression of heat shock protein (hsp)70 in the rheumatoid joint: possible mechanisms of hsp/DC-mediated cross-priming. *J Immunol* 171, 5736-42 (2003).

20. Midwood K, Sacre S, Piccinini AM *et al.*, Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. *Nat Med* 15, 774-80 (2009).

21. Pullerits R, Jonsson IM, Verdrengh M *et al.*, High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. *Arthritis Rheum* 48, 1693-700 (2003).

22. Taniguchi N, Kawahara K, Yone K *et al.*, High mobility group box chromosomal protein 1 plays a

11

role in the pathogenesis of rheumatoid arthritis as a novel cytokine. *Arthritis Rheum* 48, 971-81 (2003).

23.   Sokolove J, Zhao X, Chandra PE, Robinson WH, Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcgamma receptor. *Arthritis Rheum* 63, 53-62 (2011).

24.   Benedetti G, Miossec P, Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. *Eur J Immunol* 44, 339-47 (2014).

25.   Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P, New therapies for treatment of rheumatoid arthritis. *Lancet* 370, 1861-74 (2007).

26.   Sayed BA, Christy A, Quirion MR, Brown MA, The master switch: the role of mast cells in autoimmunity and tolerance. *Annu Rev Immunol* 26, 705-39 (2008).

27.   Crisp AJ, Chapman CM, Kirkham SE, Schiller AL, Krane SM, Articular mastocytosis in rheumatoid arthritis. *Arthritis Rheum* 27, 845-51 (1984).

28.   Malone DG, Irani AM, Schwartz LB, Barrett KE, Metcalfe DD, Mast cell numbers and histamine levels in synovial fluids from patients with diverse arthritides. *Arthritis Rheum* 29, 956-63 (1986).

29.   Olsson N, Ulfgren AK, Nilsson G, Demonstration of mast cell chemotactic activity in synovial fluid from rheumatoid patients. *Ann Rheum Dis* 60, 187-93 (2001).

30.   Gotis-Graham I, McNeil HP, Mast cell responses in rheumatoid synovium. Association of the MCTC subset with matrix turnover and clinical progression. *Arthritis and Rheumatism* 40, 479-89 (1997).

31.   McNeil HP, Gotis-Graham I, Human mast cell subsets--distinct functions in inflammation? *Inflamm Res* 49, 3-7 (2000).

32.   Buckley MG, Walters C, Wong WM *et al.*, Mast cell activation in arthritis: detection of alpha- and beta-tryptase, histamine and eosinophil cationic protein in synovial fluid. *Clin Sci (Lond)* 93, 363-70 (1997).

33.   Frewin DB, Cleland LG, Jonsson JR, Robertson PW, Histamine levels in human synovial fluid. *J Rheumatol* 13, 13-4 (1986).

34.   Lavery JP, Lisse JR, Preliminary study of the tryptase levels in the synovial fluid of patients with inflammatory arthritis. *Ann Allergy* 72, 425-7 (1994).

35.   Hueber AJ, Asquith DL, Miller AM *et al.*, Mast cells express IL-17A in rheumatoid arthritis synovium. *J Immunol* 184, 3336-40 (2010).

36.   Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA *et al.*, Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. *Arthritis Rheum* 54, 3799-808 (2006).

37.   Trouw LA, Haisma EM, Levarht EW *et al.*, Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. *Arthritis Rheum* 60, 1923-31 (2009).

38.   Nigrovic PA, Malbec O, Lu B *et al.*, C5a receptor enables participation of mast cells in immune complex arthritis independently of Fcγ receptor modulation. *Arthritis and Rheumatism* 62, 3322-33 (2010).

39.   Benhamou M, Bonnerot C, Fridman WH, Daëron M, Molecular heterogeneity of murine mast cell Fc gamma receptors. *Journal of Immunology (Baltimore, Md.: 1950)* 144, 3071-7 (1990).

40.   Fang Y, Zhang T, Lidell L *et al.*, The immune complex CTA1-DD/IgG adjuvant specifically targets connective tissue mast cells through FcγRIIIA and augments anti-HPV immunity after nasal immunization. *Mucosal Immunology* 6, 1168-78 (2013).

41.   Latour S, Bonnerot C, Fridman WH, Daëron M, Induction of tumor necrosis factor-alpha production by mast cells via Fc gamma R. Role of the Fc gamma RIII gamma subunit. *Journal of Immunology (Baltimore, Md.: 1950)* 149, 2155-62 (1992).

42.   Díaz de Ståhl T, Andrén M, Martinsson P, Verbeek JS, Kleinau S, Expression of FcgammaRIII is required for development of collagen-induced

arthritis. *European Journal of Immunology* 32, 2915-22 (2002).

43. Jonsson F, Mancardi DA, Zhao W *et al.*, Human FcgammaRIIA induces anaphylactic and allergic reactions. *Blood* 119, 2533-44 (2012).

44. Lee H, Kashiwakura J, Matsuda A *et al.*, Activation of human synovial mast cells from rheumatoid arthritis or osteoarthritis patients in response to aggregated IgG through Fcgamma receptor I and Fcgamma receptor II. *Arthritis Rheum* 65, 109-19 (2013).

45. Suurmond J, Rivellese F, Dorjee AL *et al.*, Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies. *Ann Rheum Dis* 74, 1915-23 (2015).

46. Kulka M, Alexopoulou L, Flavell RA, Metcalfe DD, Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. *J Allergy Clin Immunol* 114, 174-82 (2004).

47. Matsushima H, Yamada N, Matsue H, Shimada S, TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. *Journal of Immunology (Baltimore, Md.: 1950)* 173, 531-41 (2004).

48. McCurdy JD, Olynych TJ, Maher LH, Marshall JS, Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. *J Immunol* 170, 1625-9 (2003).

49. Varadaradjalou S, Feger F, Thieblemont N *et al.*, Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. *Eur J Immunol* 33, 899-906 (2003).

50. Piccinini AM, Midwood KS, DAMPening inflammation by modulating TLR signalling. *Mediators Inflamm* 2010, (2010).

51. Junttila IS, Watson C, Kummola L *et al.*, Efficient cytokine-induced IL-13 production by mast cells requires both IL-33 and IL-3. *J Allergy Clin Immunol* 132, 704-12 e10 (2013).

52. Xu D, Jiang H-R, Kewin P *et al.*, IL-33 exacerbates antigen-induced arthritis by activating mast cells. *Proceedings of the National Academy of Sciences* 105, 10913-8 (2008).

53. Gaudenzio N, Laurent C, Valitutti S, Espinosa E, Human mast cells drive memory CD4+ T cells toward an inflammatory IL-22+ phenotype. *J Allergy Clin Immunol* 131, 1400-7 e11 (2013).

54. Kambayashi T, Allenspach EJ, Chang JT *et al.*, Inducible MHC class II expression by mast cells supports effector and regulatory T cell activation. *J Immunol* 182, 4686-95 (2009).

55. Suurmond J, van Heemst J, van Heiningen J *et al.*, Communication between human mast cells and CD4(+) T cells through antigen-dependent interactions. *Eur J Immunol* 43, 1758-68 (2013).

56. Nakae S, Suto H, Kakurai M *et al.*, Mast cells enhance T cell activation: Importance of mast cell-derived TNF. *Proc Natl Acad Sci U S A* 102, 6467-72 (2005).

57. Baram D, Vaday GG, Salamon P *et al.*, Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha. *J Immunol* 167, 4008-16 (2001).

58. Gri G, Piconese S, Frossi B *et al.*, CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. *Immunity* 29, 771-81 (2008).

59. Kashyap M, Thornton AM, Norton SK *et al.*, Cutting edge: CD4 T cell-mast cell interactions alter IgE receptor expression and signaling. *J Immunol* 180, 2039-43 (2008).

60. Schubert N, Dudeck J, Liu P *et al.*, Mast cell promotion of T cell-driven antigen-induced arthritis despite being dispensable for antibody-induced arthritis in which T cells are bypassed. *Arthritis Rheumatol* 67, 903-13 (2015).

61. Suurmond J, Stoop JN, Rivellese F *et al.*, Activation of human basophils by combined toll-like receptor- and FcepsilonRI-triggering can promote Th2 skewing of naive T helper cells. *Eur J Immunol* 44, 386-96 (2014).

11

62. Vogelpoel LT, Hansen IS, Rispens T *et al.*, Fc gamma receptor-TLR cross-talk elicits pro-inflammatory cytokine production by human M2 macrophages. *Nat Commun* 5, 5444 (2014).

63. Gebhardt T, Sellge G, Lorentz A *et al.*, Cultured human intestinal mast cells express functional IL-3 receptors and respond to IL-3 by enhancing growth and IgE receptor-dependent mediator release. *Eur J Immunol* 32, 2308-16 (2002).

64. Lorentz A, Wilke M, Sellge G *et al.*, IL-4-induced priming of human intestinal mast cells for enhanced survival and Th2 cytokine generation is reversible and associated with increased activity of ERK1/2 and c-Fos. *J Immunol* 174, 6751-6 (2005).

65. Ochi H, De Jesus NH, Hsieh FH, Austen KF, Boyce JA, IL-4 and -5 prime human mast cells for different profiles of IgE-dependent cytokine production. *Proc Natl Acad Sci U S A* 97, 10509-13 (2000).

66. Rivellese F, Suurmond J, de Paulis A *et al.*, IgE and IL-33-mediated triggering of human basophils inhibits TLR4-induced monocyte activation. *Eur J Immunol* 44, 3045-55 (2014).

67. Kashiwakura J, Yanagisawa M, Lee H *et al.*, Interleukin-33 synergistically enhances immune complex-induced tumor necrosis factor alpha and interleukin-8 production in cultured human synovium-derived mast cells. *Int Arch Allergy Immunol* 161 Suppl 2, 32-6 (2013).

68. Abraham SN, St John AL, Mast cell-orchestrated immunity to pathogens. *Nat Rev Immunol* 10, 440-52 (2010).

69. Abraham SN, Malaviya R, Mast cells in infection and immunity. *Infect Immun* 65, 3501-8 (1997).

70. Malaviya R, Ikeda T, Ross E, Abraham SN, Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. *Nature* 381, 77-80 (1996).

71. Chen R, Ning G, Zhao ML *et al.*, Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. *J Clin Invest* 108, 1151-8 (2001).

72. Koch AE, Kunkel SL, Burrows JC et al., Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. *J Immunol* 147, 2187-95 (1991).

73. Biedermann T, Kneilling M, Mailhammer R *et al.*, Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. *J Exp Med* 192, 1441-52 (2000).

74. Nigrovic PA, Binstadt BA, Monach PA *et al.*, Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1. *Proc Natl Acad Sci U S A* 104, 2325-30 (2007).

75. Zhang Y, Ramos BF, Jakschik B *et al.*, Interleukin 8 and mast cell-generated tumor necrosis factor-alpha in neutrophil recruitment. *Inflammation* 19, 119-32 (1995).

76. Zhang Y, Ramos BF, Jakschik BA, Neutrophil recruitment by tumor necrosis factor from mast cells in immune complex peritonitis. *Science* 258, 1957-9 (1992).

77. Binstadt BA, Patel PR, Alencar H *et al.*, Particularities of the vasculature can promote the organ specificity of autoimmune attack. *Nat Immunol* 7, 284-92 (2006).

78. Lafyatis R, Remmers EF, Roberts AB *et al.*, Anchorage-independent growth of synoviocytes from arthritic and normal joints. Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids. *J Clin Invest* 83, 1267-76 (1989).

79. Pierer M, Rethage J, Seibl R *et al.*, Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. *J Immunol* 172, 1256-65 (2004).

80. Granet C, Maslinski W, Miossec P, Increased AP-1 and NF-kappaB activation and recruitment with the combination of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes. *Arthritis Res Ther* 6, R190-8 (2004).

81. Hot A, Zrioual S, Lenief V, Miossec P, IL-17 and tumour necrosis factor alpha combination induces a

HIF-1alpha-dependent invasive phenotype in synoviocytes. *Ann Rheum Dis* 71, 1393-401 (2012).

82. Sawamukai N, Yukawa S, Saito K *et al.*, Mast cell-derived tryptase inhibits apoptosis of human rheumatoid synovial fibroblasts via rho-mediated signaling. *Arthritis Rheum* 62, 952-9 (2010).

83. Zenmyo M, Hiraoka K, Komiya S, Morimatsu M, Sasaguri Y, Histamine-stimulated production of matrix metalloproteinase 1 by human rheumatoid synovial fibroblasts is mediated by histamine H1-receptors. *Virchows Arch* 427, 437-44 (1995).

84. Azizkhan RG, Azizkhan JC, Zetter BR, Folkman J, Mast cell heparin stimulates migration of capillary endothelial cells in vitro. *J Exp Med* 152, 931-44 (1980).

85. Blair RJ, Meng H, Marchese MJ *et al.*, Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. *J Clin Invest* 99, 2691-700 (1997).

86. Muramatsu M, Katada J, Hayashi I, Majima M, Chymase as a proangiogenic factor. A possible involvement of chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model. *J Biol Chem* 275, 5545-52 (2000).

87. Paleolog EM, Angiogenesis in rheumatoid arthritis. *Arthritis Res* 4 Suppl 3, S81-90 (2002).

88. Ribatti D, Mast cells and macrophages exert beneficial and detrimental effects on tumor progression and angiogenesis. *Immunol Lett* 152, 83-8 (2013).

89. Wulff BC, Wilgus TA, Mast cell activity in the healing wound: more than meets the eye? *Exp Dermatol* 22, 507-10 (2013).

90. Tolboom TC, Pieterman E, van der Laan WH *et al.*, Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. *Ann Rheum Dis* 61, 975-80 (2002).

91. Van Wart HE, Birkedal-Hansen H, The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. *Proc Natl Acad Sci U S A* 87, 5578-82 (1990).

92. Gruber BL, Schwartz LB, Ramamurthy NS, Irani AM, Marchese MJ, Activation of latent rheumatoid synovial collagenase by human mast cell tryptase. *J Immunol* 140, 3936-42 (1988).

93. Magarinos NJ, Bryant KJ, Fosang AJ *et al.*, Mast cell-restricted, tetramer-forming tryptases induce aggrecanolysis in articular cartilage by activating matrix metalloproteinase-3 and -13 zymogens. *J Immunol* 191, 1404-12 (2013).

94. Nakamura M, Kuroda H, Narita K, Endo Y, Parathyroid hormone induces a rapid increase in the number of active osteoclasts by releasing histamine from mast cells. *Life Sci* 58, 1861-8 (1996).

95. Seitz S, Barvencik F, Koehne T *et al.*, Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis. *Osteoporos Int* 24, 2325-34 (2013).

96. Lee DM, Friend DS, Gurish MF *et al.*, Mast cells: a cellular link between autoantibodies and inflammatory arthritis. *Science (New York, N.Y.)* 297, 1689-92 (2002).

97. Zhou JS, Xing W, Friend DS, Austen KF, Katz HR, Mast cell deficiency in Kit(W-sh) mice does not impair antibody-mediated arthritis. *The Journal of Experimental Medicine* 204, 2797-802 (2007).

98. Pitman N, Asquith DL, Murphy G, Liew FY, McInnes IB, Collagen-induced arthritis is not impaired in mast cell-deficient mice. *Ann Rheum Dis* 70, 1170-1 (2011).

99. Michel A, Schüler A, Friedrich P *et al.*, Mast cell-deficient Kit(W-sh) "Sash" mutant mice display aberrant myelopoiesis leading to the accumulation of splenocytes that act as myeloid-derived suppressor cells. *Journal of Immunology (Baltimore, Md.: 1950)* 190, 5534-44 (2013).

100. Nigrovic PA, Gray DHD, Jones T *et al.*, Genetic inversion in mast cell-deficient (Wsh) mice interrupts corin and manifests as hematopoietic and cardiac aberrancy. *The American Journal of Pathology* 173, 1693-701 (2008).

101. Brown MA, Hatfield JK, Mast Cells are Important Modifiers of Autoimmune Disease: With

so Much Evidence, Why is There Still Controversy? *Front Immunol* 3, 147 (2012).

102. Feyerabend TB, Weiser A, Tietz A *et al.*, Cre-mediated cell ablation contests mast cell contribution in models of antibody- and T cell-mediated autoimmunity. *Immunity* 35, 832-44 (2011).

103. Magnusson SE, Pejler G, Kleinau S, Abrink M, Mast cell chymase contributes to the antibody response and the severity of autoimmune arthritis. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology* 23, 875-82 (2009).

104. McNeil HP, Shin K, Campbell IK *et al.*, The mouse mast cell-restricted tetramer-forming tryptases mouse mast cell protease 6 and mouse mast cell protease 7 are critical mediators in inflammatory arthritis. *Arthritis Rheum* 58, 2338-46 (2008).

105. Shin K, Nigrovic PA, Crish J *et al.*, Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. *J Immunol* 182, 647-56 (2009).

106. Heger K, Fierens K, Vahl JC *et al.*, A20-deficient mast cells exacerbate inflammatory responses in vivo. *PLoS Biol* 12, e1001762 (2014).

107. Cox JS, Disodium cromoglycate (FPL 670) ('Intal'): a specific inhibitor of reaginic antibody-antigen mechanisms. *Nature* 216, 1328-9 (1967).

108. Kobayashi Y, Shirahase H, Zhao HF, Kakizoe E, Okunishi H, [Effects of orally available prodrug of cromoglycic acid on collagen-induced arthritis mice]. *Nihon Yakurigaku Zasshi* 114 Suppl 1, 154P-8P (1999).

109. Kneilling M, Hültner L, Pichler BJ *et al.*, Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice. *Arthritis and Rheumatism* 56, 1806-16 (2007).

110. Oka T, Kalesnikoff J, Starkl P, Tsai M, Galli SJ, Evidence questioning cromolyn's effectiveness and selectivity as a 'mast cell stabilizer' in mice. *Laboratory Investigation; a Journal of Technical Methods and Pathology* 92, 1472-82 (2012).